Renalytix Collaborates With ADA To Improve Early Detection Of Kidney Disease
The American Diabetes Association and Renalytix will develop a comprehensive interprofessional risk-informed Diabetes Kidney Care Pathway and Model for optimal clinical treatment and risk reduction that can be applied nationally.
You may also be interested in...
Renalytix president Tom Mclain outlined the company’s commercial strategy for its AI-powered blood test to detect early-stage kidney disease in patients with diabetes.
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights the push behind digital therapeutics, Abbott’s biowearable line, Exec Chats with iRhythm and Cognetivity, Right To Repair rules for tech, and FDA's guidance on 3D-printing.
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the fourth day of the meeting.